BR9713974A - Composição farmacêutica, processo para preparação e uso da mesma, e, processo de tratar um distúrbio de agregação de plaquetas - Google Patents

Composição farmacêutica, processo para preparação e uso da mesma, e, processo de tratar um distúrbio de agregação de plaquetas

Info

Publication number
BR9713974A
BR9713974A BR9713974-2A BR9713974A BR9713974A BR 9713974 A BR9713974 A BR 9713974A BR 9713974 A BR9713974 A BR 9713974A BR 9713974 A BR9713974 A BR 9713974A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
treating
platelet aggregation
preparing
aggregation disorder
Prior art date
Application number
BR9713974-2A
Other languages
English (en)
Other versions
BR9713974B1 (pt
Inventor
Chris Bland
Gerald Steele
Original Assignee
Astra Pharma Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Pharma Prod filed Critical Astra Pharma Prod
Publication of BR9713974A publication Critical patent/BR9713974A/pt
Publication of BR9713974B1 publication Critical patent/BR9713974B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA, PROCESSO PARA PREPARAçãO E USO DA MESMA, E, PROCESSO DE TRATAR UM DISTúRBIO DE AGREGAçãO DE PLAQUETAS". Uma composição farmacêutica compreendendo um análogo de nucleotídeo, manitol e um aditivo modificador, que é o cloreto de sódio ou um poliol que seja adequado para secagem por congelamento.
BRPI9713974-2A 1996-12-20 1997-12-11 composiÇço farmacÊutica, processo para preparaÇço e uso da mesma. BR9713974B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9604795-6 1996-12-20
SE9604795A SE9604795D0 (sv) 1996-12-20 1996-12-20 New pharmaceutical formulation
PCT/SE1997/002068 WO1998028009A1 (en) 1996-12-20 1997-12-11 Pharmaceutical compositions for freeze drying

Publications (2)

Publication Number Publication Date
BR9713974A true BR9713974A (pt) 2000-04-11
BR9713974B1 BR9713974B1 (pt) 2010-02-23

Family

ID=20405148

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9713974-2A BR9713974B1 (pt) 1996-12-20 1997-12-11 composiÇço farmacÊutica, processo para preparaÇço e uso da mesma.

Country Status (36)

Country Link
US (1) US6114313A (pt)
EP (1) EP1007094B1 (pt)
JP (1) JP4488538B2 (pt)
KR (1) KR100552880B1 (pt)
CN (1) CN1121875C (pt)
AR (1) AR010377A1 (pt)
AT (1) ATE221787T1 (pt)
AU (1) AU758857B2 (pt)
BR (1) BR9713974B1 (pt)
CA (1) CA2275153C (pt)
CZ (1) CZ300635B6 (pt)
DE (1) DE69714616T2 (pt)
DK (1) DK1007094T3 (pt)
EE (1) EE03857B1 (pt)
ES (1) ES2182133T3 (pt)
FR (1) FR15C0060I2 (pt)
HK (1) HK1026366A1 (pt)
HU (1) HU226616B1 (pt)
ID (1) ID21635A (pt)
IL (1) IL130449A0 (pt)
IS (1) IS1897B (pt)
MY (1) MY121982A (pt)
NO (1) NO327142B1 (pt)
NZ (1) NZ336027A (pt)
PL (1) PL190493B1 (pt)
PT (1) PT1007094E (pt)
RU (1) RU2205012C2 (pt)
SA (1) SA97180719B1 (pt)
SE (1) SE9604795D0 (pt)
SI (1) SI1007094T1 (pt)
SK (1) SK283137B6 (pt)
TR (1) TR199901412T2 (pt)
TW (1) TW522015B (pt)
UA (1) UA66779C2 (pt)
WO (1) WO1998028009A1 (pt)
ZA (1) ZA9711055B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702680D0 (sv) * 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
CA2778880C (en) 2009-11-11 2018-02-13 The Medicines Company Methods of treating or preventing stent thrombosis
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
BR112013020377B1 (pt) 2011-02-09 2022-06-07 Chiesi Farmaceutici S.P.A. Usos de um antagonista do receptor p2y12 reversível na fabricação de um medicamento útil para o tratamento da hipertensão pulmonar
AU2013381855B2 (en) 2013-03-09 2018-08-02 Chiesi Farmaceutici S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
EP3244900A4 (en) * 2015-01-14 2018-05-30 Chiesi Farmaceutici S.p.A. Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
MX2019015448A (es) 2017-06-23 2020-02-19 Chiesi Farm Spa Metodo para la prevencion de trombosis de desviacion de la arteria sistemica a pulmonar.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5637967B2 (pt) * 1973-05-17 1981-09-03
JPH01228915A (ja) * 1988-03-09 1989-09-12 Dai Ichi Seiyaku Co Ltd Ａｔｐ凍結乾燥製剤
GB8903593D0 (en) * 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
CZ281415B6 (cs) * 1989-11-09 1996-09-11 Masarykova Nemocnice S Poliklinikou Iii. Typu Způsob přípravy přenosového faktoru z buffy coatu savčí krve
GB9010742D0 (en) * 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
US5563122A (en) * 1991-12-09 1996-10-08 Asahi Kasei Kogyo Kabushiki Kaisha Stabilized parathyroid hormone composition

Also Published As

Publication number Publication date
CA2275153A1 (en) 1998-07-02
DE69714616D1 (de) 2002-09-12
IS5064A (is) 1999-06-03
AU5351598A (en) 1998-07-17
EP1007094A1 (en) 2000-06-14
IL130449A0 (en) 2000-06-01
HUP0000572A3 (en) 2002-10-28
NO993067L (no) 1999-08-09
UA66779C2 (uk) 2004-06-15
DK1007094T3 (da) 2002-10-28
SA97180719B1 (ar) 2006-05-13
NZ336027A (en) 2001-03-30
SE9604795D0 (sv) 1996-12-20
CN1240362A (zh) 2000-01-05
EE03857B1 (et) 2002-10-15
JP2001507022A (ja) 2001-05-29
CZ300635B6 (cs) 2009-07-08
CA2275153C (en) 2008-03-25
EP1007094B1 (en) 2002-08-07
TR199901412T2 (xx) 1999-08-23
EE9900260A (et) 2000-02-15
ZA9711055B (en) 1998-07-08
AR010377A1 (es) 2000-06-07
HUP0000572A2 (hu) 2001-05-28
ID21635A (id) 1999-07-08
HK1026366A1 (en) 2000-12-15
PL190493B1 (pl) 2005-12-30
SK283137B6 (sk) 2003-03-04
TW522015B (en) 2003-03-01
SI1007094T1 (en) 2003-02-28
FR15C0060I2 (fr) 2016-04-22
HU226616B1 (en) 2009-04-28
IS1897B (is) 2003-10-20
ES2182133T3 (es) 2003-03-01
PT1007094E (pt) 2002-12-31
CN1121875C (zh) 2003-09-24
NO327142B1 (no) 2009-05-04
CZ220199A3 (cs) 1999-11-17
JP4488538B2 (ja) 2010-06-23
BR9713974B1 (pt) 2010-02-23
US6114313A (en) 2000-09-05
WO1998028009A1 (en) 1998-07-02
DE69714616T2 (de) 2003-04-03
RU2205012C2 (ru) 2003-05-27
KR20000069598A (ko) 2000-11-25
NO993067D0 (no) 1999-06-21
AU758857B2 (en) 2003-04-03
MY121982A (en) 2006-03-31
PL334006A1 (en) 2000-01-31
FR15C0060I1 (pt) 2015-10-23
ATE221787T1 (de) 2002-08-15
KR100552880B1 (ko) 2006-02-20
SK76499A3 (en) 1999-11-08

Similar Documents

Publication Publication Date Title
BR9713974A (pt) Composição farmacêutica, processo para preparação e uso da mesma, e, processo de tratar um distúrbio de agregação de plaquetas
MX9100423A (es) Composiciones liquidas y estabilizadas para el tratamiento de la piel y fibras
BR9810703A (pt) Composição farmacêutica, e, processos para a preparação da mesma, e para tratar um distúrbio de agregação de plaqueta
BR0009213A (pt) Processos e composições para tratamento de tumores sólidos
BR9913945A (pt) Composição farmacêutica para o tratamento de distúrbios agudos por meio de administração sublingual, e, processo para o tratamento de distúrbios agudos
BR9406178A (pt) Composição de amino-açucar e glicosaminoglicano para o tratamento e restauração de tecido conectivo
BR9913948A (pt) Composição farmacêutica para o tratamento de dor aguda por administração sublingual, uso de fentanila ou um sal farmaceuticamente aceitável da mesma, e processo para o tratamento de dor aguda
ES2196026T3 (es) Uso de ndv en la fabricacion de un medicamento para tratar el cancer.
BR9711194A (pt) Uso de agente quelante clioquinol para a fabricação de uma composição farmacêutica para o tratamento de doença de alzheimer.
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
BR9706326A (pt) Composição para maquilagem ou proteção não migrável batom ou base anidra n o migrável uso de uma organopolissiloxana elastorérica sólida pelo menos parciamente reticulada processo para limitar e/ou impedir a migração de uma composição e processo de tratamento cosmético
BR9814040A (pt) Agudo no pulmão com fibrose com antagonistas de avb6
BR9001972A (pt) Agente para o tingimento oxidativo de cabelos bem como derivados de 4-amino-fenol
BR9910573A (pt) Compostos antipicornavirais, preparação e uso dos mesmos
BR9803756A (pt) Polimento da unha antipsoriático.
PT965323E (pt) Agentes e suas composicoes para o tratamento do cabelo que contem sulfatos de fucano despolimerizados
MX18106A (es) Compuesto amidinicos y composiciones usadas para el tratamiento de pneumonia por pneumocystis carinii y otras enfermedades.
ES2195184T3 (es) Preparaciones cosmeticas.
BR9710390A (pt) Siliba de compatibilidade melhorada com os aromas processo para prepara-Æo da mesma utilizacao da s¡laba e composi-Æo dentifr¡cia
BR9006567A (pt) Composto estabilizante e processos para estabilizar uma composicao de polimero natural ou sintetico e para estabilizar uma composicao de propileno
BR0009524A (pt) Uso de um composto, e, composição farmacêutica ou veterinaria
BR9005793A (pt) Composicao de fluoreto estanoso aquoso estabilizada e processo para preparacao da mesma
BR9813514A (pt) Agente para tratamento de fibras queratìnicas
BR9204852A (pt) Mistura estabilizante,composicao,uso de uma mistura e processo para estabilizar composicoes
BR9915955A (pt) Composição cosmética para cuidado com a pele, processo cosmético para tratar uma pele envelhecida e uso de 4- cromanona

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09Y Publication of grant cancelled [chapter 9.1.2 patent gazette]

Free format text: ANULADA A PUBLICACAO DE INDEFERIMENTO POR TER CIDO INDEVIDA.

B25A Requested transfer of rights approved

Owner name: ASTRAZENECA UK LIMITED (GB)

Free format text: TRANSFERIDO DE: ASTRA PHARMACEUTICALS LIMITED

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/02/2010, OBSERVADAS AS CONDICOES LEGAIS.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 23.02.2020